[
  {
    "ts": null,
    "headline": "How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook",
    "summary": "Earlier this week, Revvity reported stronger-than-expected Q4 2025 results, with Diagnostics delivering 10% reported revenue growth and management issuing upbeat full-year 2026 guidance calling for US$2.96–US$2.99 billion in revenue and adjusted EPS of US$5.35–US$5.45. Beyond the headline beat, the combination of robust Diagnostics performance and confident 2026 outlook offers investors fresh insight into how Revvity’s higher-margin, recurring revenue mix may be developing. We’ll now explore...",
    "url": "https://finnhub.io/api/news?id=ec38eaf1606c3d7ddbf59c7794afbe784e2ee4d5c4f473ef6f71d6b9aace5bef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771985385,
      "headline": "How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook",
      "id": 139203894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Earlier this week, Revvity reported stronger-than-expected Q4 2025 results, with Diagnostics delivering 10% reported revenue growth and management issuing upbeat full-year 2026 guidance calling for US$2.96–US$2.99 billion in revenue and adjusted EPS of US$5.35–US$5.45. Beyond the headline beat, the combination of robust Diagnostics performance and confident 2026 outlook offers investors fresh insight into how Revvity’s higher-margin, recurring revenue mix may be developing. We’ll now explore...",
      "url": "https://finnhub.io/api/news?id=ec38eaf1606c3d7ddbf59c7794afbe784e2ee4d5c4f473ef6f71d6b9aace5bef"
    }
  }
]